摘要
肝癌合并动脉-门静脉分流在临床上并不鲜见,严重制约并影响介入治疗的实施与效果。随着介入器材、血管超选技术、栓塞材料的发展以及近些年针对肝癌免疫及靶向药物的开发,肝癌合并动脉门静脉分流患者的预后有了明显的改善。文章旨在总结肝细胞癌合并动脉-门静脉分流的介入治疗进展,并讨论目前介入治疗中存在的挑战。
Hepatocellular carcinoma complicated with arterial-portal shunts is not uncommon in clinical practice,which seriously restricts and affects the implementation and outcome of interventional treatment.With the development of interventional devices,vascular superselection techniques,embolic materials and immune and targeted drugs for hepatocellular carcinoma in recent years,the prognosis of patients with hepatocellular carcinoma combined with arterial-portal shunts has improved significantly.The purpose of this article is to summarize the progress of interventional treatment for hepatocellular carcinoma with arterial-portal shunts and to discuss the current challenges in interventional treatment.
作者
焦盼
覃佳
陈旭颖
李超
张晓磷
Jiao Pan;Qin Jia;Chen Xuying;Li Chao;Zhang Xiaolin(Interventional Radiology Department,First Affiliated Hospital of Three Gorges University,Hubei Yichang 443001;Interventional Radiology Department,Yichang Central People's Hospital,Hubei Yichang 443000,China)
出处
《中华介入放射学电子杂志》
2022年第2期209-214,共6页
Chinese Journal of Interventional Radiology：electronic edition
关键词
肝恶性肿瘤
肝动脉化疗栓塞
肝动静脉分流
介入治疗
Hepatocellular carcinoma
Transarlerial chemoembolization
Arterio-portal shunt
Interventional therapy
作者简介
通信作者:张晓磷,Email:zhangxiaolin5800@163.com
